COVID-19, Critically Ill, Interleukin 6, Outcome, Fatal, Tocilizumab
Conditions
Keywords
COVID-19, critically ill, ICU, casirivimab imdevimab, tocilizumab, interleukin 6, C-reactive protein, ferritin, procalcitonin, mortality
Brief summary
In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr. 129/22 of the ethics commssion of the university Ulm.
Detailed description
According to the recommendations, IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight. 28-day mortality and 30-day time course of leukocyte counts and serum concentrations of C-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6) and ferritin in 4 patient groups, i. e., treated without (N) or with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T), were evaluated.
Interventions
DRUGtreated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
Sponsors
University of Ulm
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of COVID-19 * CoV-2 delta-variant * critically ill patients * ICU
Exclusion criteria
* tuberculosis * active hepatitis * HIV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rates in the 4 groups | 28-day mortality | Number of survivors and nonsurvivors |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interleukin 6 serum concentrations in 4 groups | 30-days | Routine blood analysis over time |
| Ferritin serum concentrations in 4 groups | 30-days | Routine blood analysis over time |
| Leukocyte count in 4 groups | 30-days | Routine blood analysis |
| C-reactive protein in 4 groups | 30-days | Routine blood analysis over time |
| Procalcitonin serum concentrations in 4 groups | 30-days | Routine blood analysis over time |
Countries
Germany
Outcome results
None listed